Methylene Chloride Pharmaceutical Solvent

In the isolation of basic N-heterocyclic alkaloid active pharmaceutical ingredients from aqueous botanical or fermentation broths, methylene chloride functions as the liquid-liquid extraction medium because the freebase forms of these alkaloids partition preferentially into chlorinated solvents under mildly alkaline conditions. The relevant residual solvent obligation is established by ICH Q3C, which classifies methylene chloride as a Class 2 solvent with a permitted daily exposure of 6.0 mg/day and a concentration limit of 600 ppm in the final API; batch release testing is conducted under USP <467> Procedures A, B, or C, with the same 600 ppm acceptance threshold, and the corresponding monograph is Ph Eur 5.4. Solvent addition is governed by the partition behaviour of the specific alkaloid; single-stage batch extraction typically operates at a DCM-to-aqueous feed ratio of 2:1 to 5:1 v/v, while continuous countercurrent extraction in a Karr reciprocating-plate column with 30 to 40 theoretical plates commonly uses a total solvent-to-feed ratio of 6:1 to 10:1 v/v across the stages. The downstream process includes pH adjustment of the clarified broth with sodium hydroxide to pH 8.5–9.5, extraction at 15–25 °C, separation of the lower DCM layer, drying over anhydrous calcium chloride or 4A molecular sieves to a water content below 0.05% w/w, and vacuum distillation in a falling-film or wiped-film evaporator at 35–40 °C and 500–600 mbar to avoid thermal degradation of the alkaloid freebase. The terminal finished products from this route are purified basic alkaloid salts such as vinca alkaloid sulfate APIs and related opioid alkaloid hydrochloride monographs, which are subsequently lyophilised or recrystallised for formulation into injectable and oral solid dosage forms. Because DCM is heavier than the aqueous phase, phase inversion caused by excessive solids loading above 15% w/w in the feed broth must be avoided; centrifugal separators with 316L stainless-steel contact surfaces are used instead of long gravity settlers when emulsion tendency is high.

Why Does Resin Swelling in Fmoc Solid-Phase Peptide Synthesis Require a Chlorinated Solvent?

The choice of dichloromethane in solid-phase peptide synthesis is determined by its ability to swell low-crosslink polystyrene-divinylbenzene resin supports, which increases the accessibility of the terminal amine sites for Fmoc deprotection and coupling. Equilibrium swelling volumes for 1% divinylbenzene-crosslinked polystyrene in DCM are generally reported in the range of 4.5 mL/g to 6.0 mL/g, and the solvent is therefore introduced at an initial swelling ratio of 10 mL/g to 15 mL/g of dry resin for 30–60 min before the first coupling cycle. Each post-deprotection and post-coupling wash uses 5 mL/g to 8 mL/g of DCM per resin batch, with the exact number of washes confirmed by Kaiser or TNBS resin tests rather than by fixed volume alone. Compliance for APIs produced by this route requires residual solvent control under ICH Q3C and USP <467>, with methylene chloride limited to 600 ppm in the final lyophilised peptide acetate; process validation under ICH Q7 and equipment cleaning verification under 21 CFR 211.67 are applied because peptide synthesizers are dedicated or campaign-changed between different sequences. The downstream manufacturing process is carried out in automated fixed-bed or mixed reactors with sintered-glass fritted vessels, using alternating DMF and DCM cycles, 20% piperidine in DMF for Fmoc cleavage, and DCM washes after the deprotection and capping steps to remove residual base and dibenzofulvene-piperidine adducts. Terminal finished products include therapeutic peptide APIs such as GnRH analogue acetates and synthetic somatostatin analogue acetates, which are released against residual solvent, purity, and trifluoroacetate content specifications. Drying of DCM over 3A or 4A molecular sieves is required before use in water-sensitive coupling cycles because moisture levels above 0.01% w/w reduce coupling efficiency and increase deletion impurities; DCM is not compatible with strong alkoxide bases such as sodium amide, but it remains stable under the mildly basic Fmoc conditions used on solid support.

When a Crystallization Solvent Must Be Removed Below 40 °C to Avoid Polymorph Conversion

When a thermolabile API exhibits enantiotropic polymorphic transition above 40 °C, dichloromethane is selected as the primary crystallisation solvent because its boiling point of 39.6 °C permits vacuum distillation at product temperatures below the transition threshold. The regulatory framework for this application includes ICH Q6A for polymorph decision-tree documentation, ICH Q3C and USP <467> for the residual solvent limit of 600 ppm, and Ph Eur 5.4 for monograph compliance. Formulation addition is controlled as API concentration of 80–150 mg/mL in DCM or a DCM-alcohol co-solvent system, followed by controlled addition of an n-heptane antisolvent at a volumetric antisolvent-to-solvent ratio of 2:1 to 5:1; seed crystals are introduced at 0.5–2.0 wt% of expected yield to suppress spontaneous nucleation. The downstream process uses a jacketed glass-lined crystalliser with PTFE scraper or retreat-curve impeller operating at 25–35 rpm, a cooling ramp of 0.05–0.2 °C/min, and a final hold temperature of 0–5 °C for 2–4 h; the slurry is filtered through a 0.2 µm sterilising-grade or 0.45 µm clarifying filter train, washed with pre-chilled antisolvent, and dried in a vacuum tray dryer at 30–35 °C and 50–100 mbar. Terminal finished products are crystalline APIs for injectable and lyophilised dosage forms, where polymorphic purity is confirmed by X-ray powder diffraction using a Bragg-Brentano diffractometer and differential scanning calorimetry. The operational boundary is that residual DCM in the wet cake must be reduced below 600 ppm before release, and contact surfaces should be 316L electropolished stainless steel because trace moisture in hot DCM can generate acidic decomposition products; published data for proprietary polymorph-specific processing windows is limited, so each lattice form requires laboratory-scale metastable zone width determination before scale-up.

Solvent-Borne Ethylcellulose Barrier Coating in Wurster Multiparticulate Systems

Dichloromethane is used as the volatile carrier in solvent-borne ethylcellulose barrier coating of oral multiparticulates when the core contains moisture-sensitive API or when aqueous polymer dispersions cause unacceptable drug degradation during the spray phase. The coating solution is prepared at an ethylcellulose concentration of 5% to 8% w/w in DCM, with triethyl citrate or dibutyl sebacate added at 20–30% by weight of the polymer and talc or colloidal silicon dioxide added at 40–50% by weight of the polymer to reduce tack. Compliance requires residual solvent testing under ICH Q3C and USP <467> with a methylene chloride limit of 600 ppm in the finished dosage form, release testing of drug dissolution under USP <711>, and current good manufacturing practice controls under 21 CFR 210 and 21 CFR 211. The downstream process is bottom-spray Wurster coating in a fluid-bed system with an inlet air temperature of 45–60 °C, an exhaust temperature of 25–35 °C, atomising air pressure of 1.5–2.5 bar, and a spray rate of 8–15 g/min per kg of core material; after the target weight gain of 5–20% w/w is achieved, the pellets are cured at 60 °C for 2 h to complete film coalescence and residual solvent evaporation. Terminal finished products are modified-release pellets and granules filled into hard gelatin or hypromellose capsules, or compressed into sustained-release tablets. Process boundaries are defined by the low flash point of DCM, requiring explosion-proof fluid-bed motors and exhaust LEL monitoring below 10% of the lower explosive limit; batch records must demonstrate that the residual solvent drying curve remains below 600 ppm before discharge, and coating uniformity is confirmed by scanning electron microscopy of film cross-sections and dissolution profile comparison across pellet size fractions.

Preparative normal-phase chromatographic purification of racemic API streams employs dichloromethane as the primary mobile-phase component because its low polarity and high solubilising strength allow baseline separation of enantiomers on immobilised polysaccharide chiral stationary phases. The mobile phase is typically a DCM-methanol mixture at 90:10 to 95:5 v/v, sometimes modified with 0.1–0.5% v/v diethylamine or trifluoroacetic acid to suppress peak tailing of basic or acidic racemates; feed loading is generally limited to 0.5–2.0% of column bed mass for batch preparative separations, though published compound-specific loading data for proprietary APIs is limited. Regulatory compliance for the purified API includes residual solvent control under ICH Q3C and USP <467> with a methylene chloride limit of 600 ppm, full GMP documentation under ICH Q7, and validation of the chiral method under ICH Q2(R1) for specificity, linearity, and limit of quantification. The downstream process is performed on simulated moving bed systems with 6–8 columns packed with cellulose tris(3,5-dimethylphenylcarbamate)-coated silica, monitored by UV detection at 254 nm or 280 nm; the DCM-rich fractions are evaporated in falling-film or centrifugal evaporators at 30–35 °C and 400–500 mbar, and the recovered DCM is dried over molecular sieves to below 0.05% w/w water before reuse. Terminal finished products are enantiopure single-isomer APIs for antidepressant, anticonvulsant, and proton pump inhibitor classes, where the undesired enantiomer is either recycled by racemisation or removed as a controlled waste stream. The operational boundary is that water content in the mobile phase must not exceed 0.05% w/w because moisture degrades the chiral coating and reduces column lifetime; DCM is incompatible with strong Lewis acids and should not be used in stainless-steel lines above 60 °C without drying, because hydrolytic decomposition can produce trace hydrogen chloride.

Carboxylic Acid Chloride Intermediates React with β-Lactam Nuclei in Dichloromethane Suspension

The acylation of fermentation-derived β-lactam nuclei in dichloromethane suspension is a route used for certain semisynthetic cephalosporin APIs, in which the nucleophilic amine of 7-aminocephalosporanic acid or 7-aminodeacetoxycephalosporanic acid reacts with a protected side-chain acid chloride. The reaction mixture is formulated with a substrate loading of 0.5–1.0 mol/L in DCM, an acid chloride charge of 1.05–1.20 molar equivalents relative to the β-lactam nucleus, and a tertiary amine acid scavenger such as triethylamine at 1.1–1.3 molar equivalents; published data for specific side-chain acid chlorides is limited to patent examples, and the molar ratios are narrowed by process development rather than fixed universally. Compliance includes residual solvent control under ICH Q3C and USP <467> at 600 ppm, final release under Ph Eur 5.4 and relevant USP monographs, and manufacturing documentation under ICH Q7 and 21 CFR 211.184. The downstream process is conducted in a jacketed glass-lined reactor equipped with a thermowell and addition dip-pipe, with the DCM suspension cooled to -5 °C to +5 °C before the acid chloride is added over 60–120 min; after the reaction, the mixture is quenched with 5% w/w aqueous sodium bicarbonate, the lower organic layer is separated and washed with water, and DCM is distilled under vacuum at 30–40 °C to yield the protected intermediate, which is subsequently deprotected and crystallised as the sterile sodium salt. Terminal finished products are semisynthetic cephalosporin APIs for injection, including cefazolin sodium-type and ceftriaxone sodium-type monographs. The operational boundary is that DCM-triethylamine mixtures should not be held for extended periods above 0–5 °C because dichloromethane can slowly quaternise tertiary amines; additionally, water content in the reaction mixture is maintained below 0.05% w/w to avoid hydrolysis of the acid chloride, and the reactor headspace is inerted with nitrogen because DCM vapours form flammable mixtures at elevated temperatures.